BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Covington
Baxter
Teva
Accenture
Fuji
Cipla
Express Scripts
Farmers Insurance
Medtronic

Generated: January 21, 2018

DrugPatentWatch Database Preview

Oxymetazoline hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for oxymetazoline hydrochloride and what is the scope of oxymetazoline hydrochloride freedom to operate?

Oxymetazoline hydrochloride
is the generic ingredient in four branded drugs marketed by Allergan Inc, Bayer Healthcare Llc, Johnson And Johnson, and St Renatus, and is included in four NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oxymetazoline hydrochloride has fourteen patent family members in ten countries.

There are three drug master file entries for oxymetazoline hydrochloride. One supplier is listed for this compound.
Summary for oxymetazoline hydrochloride
Pharmacology for oxymetazoline hydrochloride
Medical Subject Heading (MeSH) Categories for oxymetazoline hydrochloride

US Patents and Regulatory Information for oxymetazoline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
St Renatus KOVANAZE oxymetazoline hydrochloride; tetracaine hydrochloride SPRAY, METERED;NASAL 208032-001 Jun 29, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
St Renatus KOVANAZE oxymetazoline hydrochloride; tetracaine hydrochloride SPRAY, METERED;NASAL 208032-001 Jun 29, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
St Renatus KOVANAZE oxymetazoline hydrochloride; tetracaine hydrochloride SPRAY, METERED;NASAL 208032-001 Jun 29, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Johnson And Johnson VISINE L.R. oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 019407-001 Mar 31, 1989 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc OCUCLEAR oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 018471-001 May 30, 1986 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
St Renatus KOVANAZE oxymetazoline hydrochloride; tetracaine hydrochloride SPRAY, METERED;NASAL 208032-001 Jun 29, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for oxymetazoline hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,017,231,985 ➤ Subscribe
8,815,929 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists ➤ Subscribe
8,877,793 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for oxymetazoline hydrochloride

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
US Army
Chubb
Boehringer Ingelheim
Harvard Business School
Covington
Dow
Citi
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot